Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK agrees to pay up to $1.7 billion for antibody-drug conjugate
08:10am, Wednesday, 20'th Dec 2023
GSK PLC GSK, +0.11% said Wednesday that it has agreed to pay $185 million up front and up to $1.525 billion in success-based milestone payments to license an antibody-drug conjugate from Chinese bioph
5 Big Drug Stocks That May Continue to Outperform in 2024
10:31am, Monday, 18'th Dec 2023
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
GSK drug combination significantly improves survival in women with a hard-to-treat form of endometrial cancer
03:00am, Monday, 18'th Dec 2023
GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immuno-therapy Jemperli had shown promise when used in harness with an existing cancer drug Zejula when treating advanced or recurrent endometrial forms
GSK (GSK) Beats Stock Market Upswing: What Investors Need to Know
07:32pm, Thursday, 14'th Dec 2023
GSK (GSK) concluded the recent trading session at $36.98, signifying a +0.65% move from its prior day's close.
GSK get European green light for endometrial cancer treatment
02:59am, Monday, 11'th Dec 2023
GSK PLC (LSE:GSK, NYSE:GSK) said the European Commission had granted marketing authorization for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of advanced or recurrent en
Glaxo (GSK) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Monday, 04'th Dec 2023
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
12:47pm, Monday, 04'th Dec 2023
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
11:18am, Monday, 04'th Dec 2023
Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
These biotechs targeting multiple neurodegenerative diseases
08:15am, Friday, 01'st Dec 2023
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive
GSK plc (GSK) Presents at Redburn Atlantic CEO Conference (Transcript)
03:16pm, Wednesday, 29'th Nov 2023
GSK plc (NYSE:GSK ) Redburn Atlantic CEO Conference November 29, 2023 4:00 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Simon Baker - Redburn Simon Bak
GSK plc (GSK) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
12:33pm, Wednesday, 29'th Nov 2023
GSK plc (NYSE:GSK ) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 7:30 AM ET Company Participants Jeff McLaughlin - Director, Investor Relations Philip Dormitzer - SVP and Global Hea
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study
03:02pm, Monday, 27'th Nov 2023
GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
09:47am, Monday, 27'th Nov 2023
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.
3 Great Foreign Companies to Invest in Right Now
08:44am, Monday, 27'th Nov 2023
Adyen is a fast-growing fintech business. GSK is a major pharmaceutical company, delivering billions of vaccine doses, among other things.
GSK myeloma drug shows promise in hard-to-treat patient group
03:35am, Monday, 27'th Nov 2023
In a significant development for patients battling multiple myeloma, a type of blood cancer, GSK PLC (LSE:GSK, NYSE:GSK) has announced encouraging results from its latest phase III trial, named DREAMM
